SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.

seekingalpha.com - 2026-07-14 15:06:56

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptrend, with broader risk appetite also softer across equities.

benzinga.com - 2026-07-08 11:09:35

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company's latest corporate update.

benzinga.com - 2026-06-30 09:39:51

[url="]Amentum[/url] (NYSE: AMTM), a global leader in advanced engineering and technology solutions, has been awarded NASA's Consolidated Spaceflight Mission O

gurufocus.com - 2026-06-30 09:00:00

SELLAS Life Sciences is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing in high-risk AML settings. SLS has strengthened its cash position to $135.8 million, providing a multi-year runway and flexibility ahead of critical data and potential commercialization. The REGAL trial's delayed event count sustains optimism for GPS efficacy in CR2 AML, with topline results imminent and BLA preparation underway.

seekingalpha.com - 2026-06-27 04:25:06

Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.

invezz.com - 2026-06-26 12:30:49

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are pushing higher Friday morning, adding to Thursday's strong rally.

benzinga.com - 2026-06-26 10:54:17

Shares of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are rallying sharply Thursday, hitting a fresh 52-week high of $11.06, up over 16% in midday trading. The clinical-stage biopharmaceutical company is experiencing a massive surge in volume following a regulatory filing.

benzinga.com - 2026-06-25 14:07:40

Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher on Wednesday as traders react to the company's latest update on its acute myeloid leukemia pipeline and the timeline for a pivotal Phase 3 readout. Here's what investors need to know.

benzinga.com - 2026-05-20 09:41:40

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum Format: Corporate Presentation and Fireside Chat Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET Location: New York, NY Webcast Link: Click here A.G.P.

globenewswire.com - 2026-05-14 08:00:00

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline.

benzinga.com - 2026-05-13 10:18:30

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,” said Angelos Stergiou, MD, ScD h.c.

globenewswire.com - 2026-05-12 16:05:00

SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1 in AML, with prior phase 1/2 data showing a median OS of 21 months versus 5.4 months for standard therapy. Interim REGAL analysis showed fewer than 50% deceased at 13.5 months; final analysis at 80 events expected in 1H 2026.

seekingalpha.com - 2026-04-23 15:06:04

The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com - 2026-04-20 10:56:29